PMV Pharmaceuticals, Inc. (PMVP)

Market Cap	44.26M
Revenue (ttm)	n/a
Net Income (ttm)	-60.88M
Shares Out	51.93M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345,049
Open	0.8510
Previous Close	0.8640
Day's Range	0.8100 - 0.8793
52-Week Range	0.8210 - 2.2600
Beta	1.49
Analysts	Strong Buy
Price Target	5.50 (+545.39%)
Earnings Date	May 9, 2025

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is base...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 47
• Stock Exchange: NASDAQ
• Ticker Symbol: PMVP
• Website: https://www.pmvpharma.com

Analyst Forecast

According to 2 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 545.39% from the latest price.

Price Target

$5.5

(545.39% upside)

Analyst Consensus: Strong Buy